Loading...

Outlook Therapeutics

BST:41ON
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
41ON
BST
$35M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. The last earnings update was 66 days ago. More info.


Add to Portfolio Compare Print
  • Outlook Therapeutics has significant price volatility in the past 3 months.
41ON Share Price and Events
7 Day Returns
2.4%
BST:41ON
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
BST:41ON
-10.2%
DE Biotechs
-6%
DE Market
41ON Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Outlook Therapeutics (41ON) 2.4% -79.2% - - - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on 41ON.
  • No trading data on 41ON.
Price Volatility
41ON
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Outlook Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Outlook Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Outlook Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Outlook Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €1.3644.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Outlook Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Outlook Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:41ON PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-6.08
NasdaqCM:OTLK Share Price ** NasdaqCM (2019-04-18) in USD $1.59
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Outlook Therapeutics.

BST:41ON PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:OTLK Share Price ÷ EPS (both in USD)

= 1.59 ÷ -6.08

-0.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Outlook Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Outlook Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Outlook Therapeutics's expected growth come at a high price?
Raw Data
BST:41ON PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Outlook Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Outlook Therapeutics's assets?
Raw Data
BST:41ON PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-2.48
NasdaqCM:OTLK Share Price * NasdaqCM (2019-04-18) in USD $1.59
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
BST:41ON PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:OTLK Share Price ÷ Book Value per Share (both in USD)

= 1.59 ÷ -2.48

-0.64x

* Primary Listing of Outlook Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Outlook Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at our analysis of 41ON’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Outlook Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Outlook Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Outlook Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Outlook Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Outlook Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Outlook Therapeutics expected to grow at an attractive rate?
  • Unable to compare Outlook Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Outlook Therapeutics's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Outlook Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:41ON Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:41ON Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:41ON Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
BST:41ON Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -34 -40
2018-09-30 3 -33 -48
2018-06-30 5 -25 -43
2018-03-31 5 -22 -39
2017-12-31 4 -18 -39
2017-09-30 4 -16 -40
2017-06-30 1 -26 -43
2017-03-31 2 -36 -68
2016-12-31 2 -39 -64
2016-09-30 3 -45 -63
2016-06-30 3 -46 -71
2016-03-31 4 -40 -53

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Outlook Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if Outlook Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:41ON Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Outlook Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:41ON Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
BST:41ON Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -6.08
2018-09-30 -9.74
2018-06-30 -12.49
2018-03-31 -12.55
2017-12-31 -12.64
2017-09-30 -13.33
2017-06-30 -14.62
2017-03-31 -24.54
2016-12-31 -26.10
2016-09-30 -29.34
2016-06-30 -40.00
2016-03-31 -35.78

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Outlook Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 41ON’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Outlook Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Outlook Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Outlook Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Outlook Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Outlook Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Outlook Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Outlook Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Outlook Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Outlook Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Outlook Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Outlook Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:41ON Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.38 -40.18 13.58
2018-09-30 3.09 -48.02 14.23
2018-06-30 5.22 -42.92 11.70
2018-03-31 4.75 -39.17 12.99
2017-12-31 4.28 -38.65 14.56
2017-09-30 3.81 -40.03 15.88
2017-06-30 1.40 -43.04 18.95
2017-03-31 1.60 -67.91 25.97
2016-12-31 2.29 -64.43 21.76
2016-09-30 2.98 -63.14 21.56
2016-06-30 2.98 -70.84 19.66
2016-03-31 3.78 -53.08 11.81
2015-12-31 3.28 -63.59 16.34
2015-09-30 5.22 -53.00 12.91
2014-09-30 9.05 -20.66 7.32

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Outlook Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Outlook Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Outlook Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Outlook Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Outlook Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Outlook Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Outlook Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Outlook Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Outlook Therapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Outlook Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Outlook Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Outlook Therapeutics Company Filings, last reported 3 months ago.

BST:41ON Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -21.47 17.56 0.23
2018-09-30 -20.81 21.93 1.72
2018-06-30 -9.26 21.85 11.80
2018-03-31 -15.27 21.72 5.94
2017-12-31 -7.90 17.22 13.84
2017-09-30 -30.73 18.42 3.19
2017-06-30 -28.94 16.99 0.14
2017-03-31 -26.85 12.36 0.08
2016-12-31 -21.83 10.98 2.08
2016-09-30 -5.17 8.73 2.35
2016-06-30 1.56 9.24 13.56
2016-03-31 -37.86 14.68 2.84
2015-12-31 -30.91 15.49 5.58
2015-09-30 -42.98 21.96 9.07
2014-09-30 -32.67 15.17 2.35
  • Outlook Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Outlook Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Outlook Therapeutics has less than a year of cash runway based on current free cash flow.
  • Outlook Therapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -21.4% each year.
X
Financial health checks
We assess Outlook Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Outlook Therapeutics has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Outlook Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Outlook Therapeutics dividends.
If you bought €2,000 of Outlook Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Outlook Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Outlook Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:41ON Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:41ON Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Outlook Therapeutics has not reported any payouts.
  • Unable to verify if Outlook Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Outlook Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Outlook Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Outlook Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Outlook Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Outlook Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Outlook Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Larry Kenyon
COMPENSATION $716,132
AGE 52
TENURE AS CEO 0.8 years
CEO Bio

Mr. Lawrence A. Kenyon, also known as Larry, CPA, has been Chief Financial Officer, Treasurer and Corporate Secretary of Outlook Therapeutics, Inc. since September 15, 2015. He has been a Director, Chief Executive Officer and President of Outlook Therapeutics, Inc. since August 2, 2018. He had served as Interim CEO at Outlook Therapeutics, Inc. from June 18, 2018 to August 2018. Mr. Kenyon served as the Chief Financial Officer of Arno Therapeutics, Inc. from February 27, 2014 to September 15, 2015 and as its Chief Operating Officer from July 18, 2014 to September 15, 2015 and also served as its Principal Accounting Officer. Mr. Kenyon served as the Chief Executive Officer of Tamir Biotechnology, Inc. (formerly known as Alfacell Corp.) until March 31, 2013 and served as its Chief Financial Officer since December 23, 2011 and served as its President and Corporate Secretary. Mr. Kenyon served as an Interim Chief Executive Officer of Tamir Biotechnology, Inc. since December 23, 2011 and served as its acting president from December 2008 to January 2009. Mr. Kenyon served as the Chief Financial Officer and Executive Vice President of Par Pharmaceutical Companies Inc. from March 9, 2009 to June 30, 2010. Mr. Kenyon has strong financial, investor relations and leadership skills. Mr. Kenyon served as Acting President, Acting Chief Financial Officer and Acting Corporate Secretary of Alfacell Corp. from December 2008 to January 31, 2009. Mr. Kenyon was responsible for all financial aspects of Alfacell. Mr. Kenyon served as an Executive Vice President of Finance at Par Pharmaceutical Companies Inc. and Par Pharmaceutical, Inc. since December 15, 2008. He served as the Chief Financial Officer and Company Secretary of Alfacell Corp. from January 17, 2007 to December 2008. He served as Chief Operating Officer of Alfacell Corp. from November 2007 to December 2008 and its Principal Accounting Officer and President until December 2008. He served as Executive Vice President of Alfacell Corp. since January 17, 2007. Mr. Kenyon served as Chief Financial Officer of NeoPharm Inc. from September 2000 to August 31, 2006 and also served as its Corporate Secretary and Executive Vice President until August 31, 2006. Mr. Kenyon began his career with Arthur Andersen & Co. From October 1999 to September 2000, he served as Senior Vice President of the Gabelli Mathers Fund. From 1988 to 2000, Mr. Kenyon held a variety of senior executive positions with Mathers & Company, Inc. and its affiliated companies most recently as a chief financial officer. He served as a Director of Alfacell Corp., from November 2007 to January 31, 2009. Mr. Kenyon holds a B.A. in Accounting from the University of Wisconsin—Whitewater in 1987. He is a Certified Public Accountant in Illinois.

CEO Compensation
  • Larry's compensation has increased whilst company is loss making.
  • Larry's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Outlook Therapeutics management team in years:

1
Average Tenure
54.5
Average Age
  • The average tenure for the Outlook Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Larry Kenyon

TITLE
President
COMPENSATION
$716K
AGE
52
TENURE
0.8 yrs

Pankaj Mohan

TITLE
Founder & Director
COMPENSATION
$1M
AGE
53
TENURE
8.3 yrs

Kenneth Bahrt

TITLE
Chief Medical Officer
COMPENSATION
$429K
AGE
65
TENURE
3.8 yrs

Terry Dagnon

TITLE
Chief Operating Officer
AGE
56
TENURE
0.4 yrs

Rick Gregory

TITLE
Director of Marketing & Communications

Jeff Evanson

TITLE
Chief Commercial Officer
AGE
49
TENURE
0.4 yrs

Balu Balasubramanian

TITLE

Liz Yamashita

TITLE
COMPENSATION
$252K
AGE
57
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Outlook Therapeutics board of directors in years:

6.9
Average Tenure
55
Average Age
  • The tenure for the Outlook Therapeutics board of directors is about average.
Board of Directors

Randy Thurman

TITLE
Executive Chairman
COMPENSATION
$133K
AGE
69
TENURE
0.8 yrs

Larry Kenyon

TITLE
President
COMPENSATION
$716K
AGE
52
TENURE
0.7 yrs

Pankaj Mohan

TITLE
Founder & Director
COMPENSATION
$1M
AGE
53
TENURE
8.3 yrs

Joseph Bertino

TITLE
Chairman of Scientific Advisory Board
TENURE
6.9 yrs

Kurt Hilzinger

TITLE
Independent Director
COMPENSATION
$84K
AGE
57
TENURE
3.3 yrs

Faisal Sukhtian

TITLE
Director
AGE
34
TENURE
1.6 yrs

Debabrata Banerjee

TITLE
Member of Scientific Advisory Board
AGE
61
TENURE
6.9 yrs

Igor Astsaturov

TITLE
Member of Scientific Advisory Board
TENURE
6.9 yrs

Hossein Borghaei

TITLE
Member of Scientific Advisory Board
TENURE
6.9 yrs

Matthew Robinson

TITLE
Member of Scientific Advisory Board
TENURE
6.9 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Outlook Therapeutics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Feb 19 Buy Lawrence Kenyon Individual 07. Feb 19 07. Feb 19 3,125 €6.31 €19,708
06. Feb 19 Buy Kurt Hilzinger Individual 04. Feb 19 04. Feb 19 748 €5.60 €4,188
01. Feb 19 Buy Kurt Hilzinger Individual 30. Jan 19 01. Feb 19 2,424 €5.36 €12,680
30. Jan 19 Buy Kurt Hilzinger Individual 25. Jan 19 29. Jan 19 4,014 €5.11 €19,859
25. Jan 19 Buy Kurt Hilzinger Individual 22. Jan 19 23. Jan 19 1,627 €4.78 €7,751
18. Jan 19 Buy Kurt Hilzinger Individual 16. Jan 19 17. Jan 19 388 €4.85 €1,872
17. Jan 19 Buy Pankaj Mohan Individual 15. Jan 19 15. Jan 19 1,000 €4.77 €4,774
16. Jan 19 Buy Kurt Hilzinger Individual 14. Jan 19 15. Jan 19 833 €4.98 €4,133
11. Jan 19 Buy Kurt Hilzinger Individual 09. Jan 19 10. Jan 19 1,106 €5.07 €5,451
09. Jan 19 Buy Kurt Hilzinger Individual 04. Jan 19 08. Jan 19 2,223 €4.54 €9,683
03. Jan 19 Buy Kurt Hilzinger Individual 31. Dec 18 03. Jan 19 2,149 €4.14 €8,891
28. Dec 18 Buy Kurt Hilzinger Individual 26. Dec 18 28. Dec 18 2,294 €3.77 €8,431
26. Dec 18 Buy Kurt Hilzinger Individual 21. Dec 18 24. Dec 18 589 €4.63 €2,695
21. Dec 18 Buy Ralph Thurman Individual 21. Dec 18 21. Dec 18 1,875 €4.79 €8,982
18. Sep 18 Sell Lawrence Kenyon Individual 18. Sep 18 18. Sep 18 -1,263 €5.97 €-7,536
27. Jun 18 Sell Kenneth Bahrt Individual 25. Jun 18 25. Jun 18 -963 €5.78 €-5,564
X
Management checks
We assess Outlook Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Outlook Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.

Details
Name: Outlook Therapeutics, Inc.
41ON
Exchange: BST
Founded: 2010
$31,244,215
22,099,022
Website: http://www.outlooktherapeutics.com
Address: Outlook Therapeutics, Inc.
7 Clarke Drive,
Cranbury,
New Jersey, 08512,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM OTLK Common Stock Nasdaq Capital Market US USD 28. May 2016
BST 41ON Common Stock Boerse-Stuttgart DE EUR 28. May 2016
Number of employees
Current staff
Staff numbers
56
Outlook Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:16
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2017/06/21
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.